NGM Biopharmaceuticals, Inc.
333 Oyster Point Boulevard
South San Francisco
California
94080
United States
137 articles about NGM Biopharmaceuticals, Inc.
-
NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results
3/11/2024
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today provided recent business highlights and reported financial results for the fourth quarter and full year ended December 31, 2023.
-
NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP
2/26/2024
NGM Biopharmaceuticals, Inc. announced that it has entered into a definitive Agreement and Plan of Merger under which Atlas Neon Parent, Inc. and Atlas Neon Merger Sub, Inc. will acquire NGM Bio through a cash tender offer to be commenced by Merger Sub for all outstanding shares of NGM Bio not held by affiliates of The Column Group, LP and certain other stockholders, as described below, at a price per share of $1.55 in cash.
-
NGM Bio to Participate in the Cowen 44th Annual Health Care Conference
2/20/2024
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM) today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will participate in a corporate panel discussion on novel oncology targets at the Cowen 44th Annual Health Care Conference on Tuesday, March 5th, at 9:10 am ET.
-
NGM Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference
1/17/2024
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM) today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, and Jean-Frédéric Viret, Ph.D., Chief Financial Officer, will participate in the B. Riley Securities 4th Annual Oncology Conference and will provide a business update focusing on NGM Bio’s wholly-owned oncology portfolio on Thursday, January 18th, at 2:30 pm ET.
-
NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet Need
1/9/2024
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced encouraging new data from an ongoing Phase 1 Part 1b study evaluating NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, in combination with KEYTRUDA® (pembrolizumab).
-
NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting®
11/13/2023
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM) today shared positive, comprehensive results from its Phase 2b ALPINE 4 trial of aldafermin, an engineered FGF19 analog product candidate, in patients with compensated cirrhosis (liver fibrosis stage 4 or F4) due to NASH in an oral plenary presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®.
-
NGM Bio to Participate in Upcoming November 2023 Investor Conferences
11/7/2023
NGM Biopharmaceuticals, Inc. announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming 6th Annual Evercore ISI HealthCONx Conference and will present an overview of the company and provide a business update.
-
NGM Bio Reports Third Quarter 2023 Financial Results and Provides Business Highlights
11/2/2023
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a clinical-stage biotechnology company focused on discovering and developing transformative therapeutics for patients, today reported financial results for the quarterly period ended September 30, 2023 and provided business highlights.
-
NGM Bio Announces Oral Plenary Presentation of Data from Phase 2b ALPINE 4 Trial of Aldafermin in Compensated Cirrhosis (F4) Due to NASH at Upcoming AASLD The Liver Meeting®
10/11/2023
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM) today announced that an abstract related to comprehensive results from the company’s Phase 2b ALPINE4 trial of aldafermin in patients with compensated cirrhosis (liver fibrosis stage 4, or, F4) due to nonalcoholic steatohepatitis (NASH) has been selected for an oral plenary presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, which will take place November 10-14, 2023, in Boston, MA.
-
NGM Bio Reports Second Quarter 2023 Financial Results and Provides Business Highlights
8/3/2023
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a clinical-stage biotechnology company focused on discovering and developing transformative therapeutics for patients, today reported financial results for the quarterly period ended June 30, 2023 and provided business highlights.
-
NGM Bio to Participate in Upcoming Investor Conferences - May 25, 2023
5/25/2023
NGM Biopharmaceuticals, Inc. announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an overview of the company and provide a business update at the following upcoming investor conferences.
-
NGM Bio Reports First Quarter 2023 Financial Results and Provides Business Highlights, Including Topline ALPINE 4 Data
5/4/2023
NGM Biopharmaceuticals, Inc., a clinical-stage biotechnology company focused on discovering and developing transformative therapeutics for patients, reported financial results for the quarterly period ended March 31, 2023 and provided business highlights.
-
NGM Bio to Participate in the Cowen 43rd Annual Health Care Conference
3/1/2023
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM) today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will participate in the Cowen 43rd Annual Health Care Conference as part of the Novel Oncology Targets Panel and will provide a business update focusing on NGM Bio’s wholly-owned oncology portfolio on Tuesday, March 7th, at 9:10 am ET.
-
NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial Results
2/28/2023
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today provided business highlights and reported financial results for the fourth quarter and full year ended December 31, 2022.
-
NGM Bio to Participate in the B. Riley Securities 3rd Annual Oncology Conference
1/12/2023
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM) today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, and Siobhan Nolan Mangini, President and Chief Financial Officer, will participate in the B. Riley Securities 3rd Annual Oncology Conference and will provide a business update focusing on NGM Bio’s wholly-owned oncology portfolio on Thursday, January 19th, at 11:00 am ET.
-
NGM Bio Outlines Corporate Strategy and Provides Guidance on Key Priorities
1/9/2023
NGM Biopharmaceuticals, Inc. is providing an overview of highlights from 2022 and outlining its 2023 corporate priorities.
-
NGM Bio Gives Presentation Featuring Preclinical Characterization of NGM936 at 2022 ASH Annual Meeting
12/12/2022
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, provided additional detail today on the poster presentation given on the Company’s first disclosed preclinical bispecific program, NGM936, at the American Society of Hematology (ASH) Annual Meeting.
-
NGM Bio Presents Preliminary Data from Phase 1 Monotherapy Dose Escalation Trial of NGM707 in Patients with Advanced or Metastatic Solid Tumors at 2022 ESMO-IO Annual Meeting
12/7/2022
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM) today announced the presentation of preliminary data from the Phase 1 Part 1a monotherapy dose escalation arm of the ongoing Phase 1/2 trial of NGM707 in patients with advanced or metastatic solid tumors at the European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Annual Congress, which is taking place December 7 – 9, 2022 in Geneva, Switzerland.
-
NGM Bio Announces Poster Presentation Featuring Initial Findings from Ph1a Trial of NGM707 in Patients with Advanced Solid Tumors at Upcoming 2022 ESMO-IO Annual Meeting
11/7/2022
NGM Biopharmaceuticals, Inc. announced that an abstract related to the Company’s lead myeloid reprogramming and checkpoint inhibition program, NGM707, has been accepted for presentation at the European Society for Medical Oncology Immuno-Oncology Annual Congress, which will take place December 7 – 9, 2022 at the Palexpo Exhibition Centre in Geneva, Switzerland.
-
NGM Bio Provides Business Highlights and Reports Third Quarter 2022 Financial Results
11/3/2022
NGM Biopharmaceuticals, Inc., a clinical-stage biotechnology company focused on discovering and developing transformative therapeutics for patients, provided business highlights and reported financial results for the quarterly period ended September 30, 2022.